Wel­come back to End­points Week­ly — thanks for start­ing your Sat­ur­day with us. It was a busy week in the bio­phar­ma world. FDA Com­mis­sion­er Mar­ty Makary … ...

Insilico Medicine files third HKEX IPO attempt, as biotech develops rentosertib for IPF and other drugs with AI-driven ...

Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen ...

Endpoints platform launches new profile system with improved account management features, including streamlined newsletter ...

Patrik Jonsson becomes International president, Ilya Yuffa leads USA division, Kenneth Custer takes over Cardiometabolic ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...

Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price up by as much as 35% ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...